- Home
- CIGI vs PCVX Comparison
CIGI vs PCVX Comparison
Compare CIGI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIGI | PCVX |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CIGI | PCVX |
|---|---|---|
| Price | $118.30 | $58.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $174.00 | $98.33 |
| AVG Volume (30 Days) | 589.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.74 | N/A |
| Revenue Next Year | $8.04 | N/A |
| P/E Ratio | $57.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.97 | $28.09 |
| 52 Week High | $171.20 | $76.61 |
Technical Indicators
Market Signals| Indicator | CIGI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 55.14 |
| Support Level | $98.97 | $42.30 |
| Resistance Level | $121.40 | $65.00 |
| Average True Range (ATR) | 3.69 | 3.01 |
| MACD | 0.70 | -0.48 |
| Stochastic Oscillator | 25.83 | 43.40 |
Price Performance
Historical ComparisonAbout CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.